Pegcetacoplan

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NamePegcetacoplan
Drug Alias NameAspaveliEmpaveliSyfovreAPL-2
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsRejection of renal transplantationC3 glomerulopathyIschemic Stroke +[17] 
Global Approved IndicationsHemoglobinuria, Paroxysmal
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/05/14
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesApellis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSwedish Orphan Biovitrum AgSobiSwedish Orphan Biovitrum (Sobi) +[7] 
Inactive CompaniesApellis Europe Bv
Active IndicationsRejection of renal transplantationC3 glomerulopathyIschemic Stroke +[14] 
Inactive IndicationsMacular DegenerationMotor Neuron DiseaseAmyotrophic Lateral Sclerosis

Other Information

ATC CodeB03XA
Related LinksWikipediaDrugBankKEGG